These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 305966)

  • 21. Nonspecific resistance to tumor allograft.
    Rejthar A; Wotke J; Rejtharová A; Jasková J
    Neoplasma; 1975; 22(3):273-8. PubMed ID: 1099469
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immune response to a syngeneic mammary adenocarcinoma. I. Comparison of kinetics of tumor cell growth and cytotoxic responses in syngeneic and allogeneic rats.
    Fortner GW; Kuperman O; Lucas ZJ
    J Immunol; 1975 Nov; 115(5):1269-76. PubMed ID: 1080776
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Induction of graft-versus-leukemia (GVL) activity in murine leukemia models after IL-2 pretreatment of syngeneic and allogeneic bone marrow grafts.
    Zeis M; Uharek L; Glass B; Gaska T; Gassmann W; Mueller-Ruchholtz W
    Bone Marrow Transplant; 1994 Nov; 14(5):711-5. PubMed ID: 7889004
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of cytostasis in antitumor immunity: comparison between syngeneic and allogeneic systems.
    Mitani M; Mori K; Himeno K; Matsumoto T; Taniguchi K; Nomoto K
    Cell Immunol; 1985 Apr; 92(1):22-30. PubMed ID: 4075412
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lewis lung tumor system as a model for studying the immune function in syngeneic in equillibrium allogeneic chimeras.
    Elbling L; Kurata T; Micksche M
    Oncology; 1977; 34(5):209-11. PubMed ID: 917453
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Analysis of the mechanism of allograft rejection and cell-mediated immunity. I. Accelerated rejection of tumour allografts without augmented cytotoxicity in the spleen cells.
    Nanishi F; Nomoto K; Taniguchi K; Kubo C
    Immunology; 1980 May; 40(1):67-76. PubMed ID: 7419243
    [TBL] [Abstract][Full Text] [Related]  

  • 27. BCG-induced protection against malignant melanoma: possible immunospecific effect in a murine system.
    Faraci RP; Barone J; Schour L
    Cancer; 1975 Feb; 35(2):372-7. PubMed ID: 1111914
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mechanisms of BCG action. I. The induction of nonspecific helper cells during the potentiation of alloimmune cell-mediated cytotoxic responses.
    Davies M; Sabbadini E
    Cancer Immunol Immunother; 1982; 14(1):46-53. PubMed ID: 6218872
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vitro reactivity of splenic lymphocytes from normal and UV-irradiated mice against syngeneic UV-induced tumors.
    Fortner GW; Kripke ML
    J Immunol; 1977 Apr; 118(4):1483-7. PubMed ID: 66296
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunopotentiation with BCG. IV. Factors affecting the magnitude of an antitumor response.
    Hawrylko E; Mackaness GB
    J Natl Cancer Inst; 1973 Nov; 51(5):1683-8. PubMed ID: 4587143
    [No Abstract]   [Full Text] [Related]  

  • 31. In vivo targeting of an anti-tumor antibody coupled to antigenic MHC class I complexes induces specific growth inhibition and regression of established syngeneic tumor grafts.
    Donda A; Cesson V; Mach JP; Corradin G; Primus FJ; Robert B
    Cancer Immun; 2003 Aug; 3():11. PubMed ID: 12916958
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Cytotoxic effect of BCG-activated macrophages on tumor target cells in vitro].
    Viadro MM
    Biull Eksp Biol Med; 1979 Jan; 87(1):36-9. PubMed ID: 760842
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relationship between intradermal tumor suppression and tumor immunity.
    Bartlett GL; Kreider JW; Purnell DM
    J Natl Cancer Inst; 1976 Dec; 57(6):1297-303. PubMed ID: 794505
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ability of spleen cells from tumor bearing mice to transfer immunologic memory.
    Plavsić B; Jurin M; Ugarković B
    Acta Radiol Oncol; 1983; 22(5):385-8. PubMed ID: 6320597
    [TBL] [Abstract][Full Text] [Related]  

  • 35. LY-2+ effectors cytotoxic for syngeneic tumor cells: generation by allogeneic stimulation and by supernatants from mixed leukocyte cultures.
    Hurrell SM; Zarling JM
    J Immunol; 1983 Aug; 131(2):1017-23. PubMed ID: 6223084
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immune responses to mouse neuroblastoma C1300. I. Preliminary observations on cell-mediated immune responses.
    Phillips ME; Cipuzak PM; Penta DD; Schachner M
    J Natl Cancer Inst; 1977 Oct; 59(4):1215-9. PubMed ID: 903996
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Modulation of cell-mediated alloimmunity by BCG. II. Induction of specific, nonadherent, non-T-killer cells by BCG and alloantigen.
    Murahata RI; Mitchell MS
    J Natl Cancer Inst; 1982 Sep; 69(3):613-8. PubMed ID: 6810008
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Allogeneic tumor-syngeneic muscle sandwich grafts: a method for promoting nonspecific growth.
    Parks RC
    J Natl Cancer Inst; 1976 Jun; 56(6):1281-4. PubMed ID: 994227
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Immunopotentiation with BCG: dimensions of a specific antitumor response.
    Hawrylko E
    J Natl Cancer Inst; 1975 May; 54(5):1189-97. PubMed ID: 805254
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Enhancing effect of coenzyme, Q10 on immunorestoration with Mycobacterium bovis BCG in tumor-bearing mice.
    Kawase I; Niitani H; Saijo N; Sasaki H; Morita T
    Gan; 1978 Aug; 69(4):493-7. PubMed ID: 101414
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.